Interim analysis of a single-arm, phase II study of bevacizumab (BV) with modified OPTIMOX1 as first-line treatment of patients with metastatic colorectal cancer (mCRC): TCOG-GI0802

被引：0
|
作者：
Asano, M. [1 ]
Tanaka, S. [1 ]
Sato, A. [1 ]
Nakayama, N. [1 ]
Shimada, K. [1 ]
Konishi, K. [1 ]
Hibi, K. [1 ]
Sasaki, E. [1 ]
Kurihara, M. [1 ]
机构：
[1] Tokyo Cooperat Oncol Grp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
578
引用
收藏
页数：1
相关论文
共 50 条
  • [21] mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study
    Tournigand, C.
    Samson, B.
    Scheithauer, W.
    Louvet, C.
    Andre, T.
    Lledo, G.
    Latreille, J.
    Viret, F.
    Chibaudel, B.
    de Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single-arm phase II study of bevacizumab and RAD001
    Treiber, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer
    Puthillath, Ajithkumar
    Mashtare, Terry, Jr.
    Wilding, Gregory
    Khushalani, Nikhil
    Steinbrenner, Lynn
    Ross, Mary Ellen
    Romano, Karen
    Wisniewski, Michelle
    Fakih, Marwan G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (03) : 242 - 248
  • [24] First-line treatment of metastatic colorectal cancer (MCRC) with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the GONO group
    Masi, G.
    Loupakis, F.
    Baldi, G.
    Fornaro, L.
    Stasi, I
    Vasile, E.
    Cialo, A.
    Cavaciocchi, D.
    Di Leo, A.
    Puglisi, M.
    Ciprotti, M.
    Amoroso, D.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [25] FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the GONO group
    Falcone, A.
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Amoroso, D.
    Puglisi, M.
    Fea, E.
    Brunetti, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] PHASE II STUDY OF FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) WITH GONO-FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) PLUS BEVACIZUMAB (BV)
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Ciprotti, M.
    Donati, S.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 137
  • [27] Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Greil, R.
    Letocha, H.
    Gamelin, E.
    Thaler, J.
    Hofheinz, R.
    Mineur, L.
    Fernebro, E.
    Karthaus, M.
    Wright, L.
    Koehne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] First-line treatment for metastatic colorectal cancer (MCRC) patients (pts). Results of a randomized phase IIITMO study
    Bajetta, E.
    Di Bartolomeo, M.
    Ferrario, E.
    Beretta, E.
    Rabbi, C.
    Isa, L.
    Barone, C.
    Lo, S.
    Zilembo, Vullo N.
    ANNALS OF ONCOLOGY, 2005, 16 : 48 - 48
  • [29] A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma
    Fruehauf, John P.
    Alger, Beverly
    Jakowatz, James G.
    Hsiang, David
    Sender, Leonard S.
    Bettis, Claudette
    Casey, Cameron
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
12345